DOCSLIB.ORG

Studies Describing Baseline Dialysate Concentrations for Asparagine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Studies Describing Baseline Dialysate Concentrations for Asparagine Appendix 1: Studies describing baseline dialysate concentrations for asparagine Asparagine Authors Title Year Vol Pages Journal Abraham, I.; Juhasz, G.; Kekesi, K. A.; Corticosterone peak is responsible for stress-induced elevation of 1998 2 171-181 Stress Kovacs, K. J. glutamate in the hippocampus Abraham, I.; Juhasz, G.; Kekesi, K. A.; Effect of intrahippocampal dexamethasone on the levels of amino 1996 733 56-63 Brain Res Kovacs, K. J. acid transmitters and neuronal excitability Acworth, I. N.; Yu, J.; Ryan, E.; Gariepy, K. Simultaneous measurement of monoamine, amino acid, and drug 1994 17 685-705 J Liq Chromatogr C.; Gamache, P.; Hull, K.; Maher, T. levels, using high performance liquid chromatography and coulometric array technology: Application to in vivo microdialysis perfusate analysis Andine, P.; Orwar, O.; Jacobson, I.; Changes in extracellular amino acids and spontaneous neuronal 1991 57 222-229 J Neurochem Sandberg, M.; Hagberg, H. activity during ischemia and extended reflow in the CA1 of the rat hippocampus Bereiter, D. A.; Shen, S.; Benetti, A. P. Sex differences in amino acid release from rostral trigeminal 2002 98 89-99 Pain subnucleus caudalis after acute injury to the TMJ region Boyd, B. W.; Witowski, S. R.; Kennedy, R. T. Trace-level amino acid analysis by capillary liquid chromatography 2000 72 865-871 Anal Chem and application to in vivo microdialysis sampling with 10-s temporal resolution Buisson, A.; Callebert, J.; Mathieu, E.; Striatal protection induced by lesioning the substantia nigra of rats 1992 59 1153- J Neurochem Plotkine, M.; Boulu, R. G. subjected to focal ischemia 1157 Butcher, S. P.; Hamberger, A. In vivo studies on the extracellular, and veratrine-releasable, pools 1987 48 713-721 J Neurochem of endogenous amino acids in the rat striatum: effects of corticostriatal deafferentation and kainic acid lesion Butcher, S. P.; Jacobson, I.; Hamberger, A. On the epileptogenic effects of kainic acid and dihydrokainic acid in 1988 27 375-381 Neuropharmacol the dentate gyrus of the rat Butcher, S. P.; Lazarewicz, J. W.; In vivo microdialysis studies on the effects of decortication and 1987 49 1355- J Neurochem Hamberger, A. excitotoxic lesions on kainic acid-induced calcium fluxes, and 1360 endogenous amino acid release, in the rat striatum Butcher, S. P.; Sandberg, M.; Hagberg, H.; Cellular origins of endogenous amino acids released into the 1987 48 722-728 J Neurochem Hamberger, A. extracellular fluid of the rat striatum during severe insulin-induced hypoglycemia Choi, Y. H.; Chang, N.; Fletcher, P. J.; Dietary protein content affects the profiles of extracellular amino 2000 66 1105- Life Sci Anderson, G. H. acids in the medial preoptic area of freely moving rats 1118 Asparagine Authors Title Year Vol Pages Journal Choi, Y. H.; Fletcher, P. J.; Anderson, G. H. Extracellular amino acid profiles in the paraventricular nucleus of the 2001 892 320-328 Brain Res rat hypothalamus are influenced by diet composition Currie, P. J.; Chang, N.; Luo, S.; Anderson, Microdialysis as a tool to measure dietary and regional effects on 1995 57 1911- Life Sci G. H. the complete profile of extracellular amino acids in the 1923 hypothalamus of rats David, C. N.; Frias, E. S.; Szu, J. I.; Vieira, GLT-1-Dependent Disruption of CNS Glutamate Homeostasis and 2016 12 e1005643 PLoS Pathog P. A.; Hubbard, J. A.; Lovelace, J.; Michael, Neuronal Function by the Protozoan Parasite Toxoplasma gondii M.; Worth, D.; McGovern, K. E.; Ethell, I. M.; Stanley, B. G.; Korzus, E.; Fiacco, T. A.; Binder, D. K.; Wilson, E. H. Dolgodilina, E.; Imobersteg, S.; Laczko, E.; Brain interstitial fluid glutamine homeostasis is controlled by blood- 2016 36 1929- J Cereb Blood Flow Metab Welt, T.; Verrey, F.; Makrides, V. brain barrier SLC7A5/LAT1 amino acid transporter 1941 Fedele, E.; Foster, A. C. An evaluation of the role of extracellular amino acids in the delayed 1993 52 911-917 Neuroscience neurodegeneration induced by quinolinic acid in the rat striatum Fraser, M.; Bennet, L.; Van Zijl, P. L.; Extracellular amino acids and lipid peroxidation products in 2008 105 2214- J Neurochem Mocatta, T. J.; Williams, C. E.; Gluckman, P. periventricular white matter during and after cerebral ischemia in 2223 D.; Winterbourn, C. C.; Gunn, A. J. preterm fetal sheep Gobert, A.; Rivet, J. M.; Billiras, R.; Parsons, Simultaneous quantification of D- vs. L-serine, taurine, kynurenate, 2011 202 143-157 J Neurosci Methods F.; Millan, M. J. phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: differential modulation by N-methyl- D-aspartate (NMDA) and other pharmacological agents Goldsmith, J. D.; Kujawa, S. G.; McLaren, J. In vivo release of neuroactive amino acids from the inferior colliculus 1995 83 80-88 Hear Res D.; Bledsoe Jr, S. C. of the guinea pig using brain microdialysis Gordon, K. E.; Simpson, J.; Statman, D.; Effects of perinatal stroke on striatal amino acid efflux in rats studied 1991 22 928-932 Stroke Silverstein, F. S. with in vivo microdialysis Guerra-Romero, L.; Tureen, J. H.; Fournier, Amino acids in cerebrospinal and brain interstitial fluid in 1993 33 510-513 Pediatr Res M. A.; Makrides, V.; Tauber, M. G. experimental pneumococcal meningitis Haskew-Layton, R. E.; Rudkouskaya, A.; Two distinct modes of hypoosmotic medium-induced release of 2008 3 e3543 PLoS One Jin, Y.; Feustel, P. J.; Kimelberg, H. K.; excitatory amino acids and taurine in the rat brain in vivo Mongin, A. A. Jacobson, I.; Sandberg, M.; Hamberger, A. Mass transfer in brain dialysis devices--a new method for the 1985 15 263-268 J Neurosci Methods estimation of extracellular amino acids concentration Largo, C.; Cuevas, P.; Somjen, G. G.; Martin The effect of depressing glial function in rat brain in situ on ion 1996 16 1219- J Neurosci Asparagine Authors Title Year Vol Pages Journal del Rio, R.; Herreras, O. homeostasis, synaptic transmission, and neuron survival 1229 Lehmann, A. Alterations in hippocampal extracellular amino acids and purine 1987 22 573-578 Neuroscience catabolites during limbic seizures induced by folate injections into the rabbit amygdala Lerma, J.; Herranz, A. S.; Herreras, O. In vivo determination of extracellular concentration of amino acids in 1986 384 145-155 Brain Research the rat hippocampus. A method based on brain dialysis and computerized analysis Li, H.; Yan, Z. Y. Analysis of amino acid neurotransmitters in hypothalamus of rats 2010 24 1185- Biomed Chromatogr during cerebral ischemia-reperfusion by microdialysis and capillary 1192 electrophoresis Li, Z. P.; Zhang, X. Y.; Lu, X.; Zhong, M. K.; Dynamic release of amino acid transmitters induced by valproate in 2004 44 263-270 Neurochem Int Ji, Y. H. PTZ-kindled epileptic rat hippocampus Lo, E. H.; Steinberg, G. K.; Panahian, N.; Profiles of extracellular amino acid changes in focal cerebral 1993 15 281-287 Neurol Res Maidment, N. T.; Newcomb, R. ischaemia: effects of mild hypothermia Malmberg, A. B.; Hamberger, A.; Hedner, T. Effects of prostaglandin E2 and capsaicin on behavior and 1995 65 2185- J Neurochem cerebrospinal fluid amino acid concentrations of unanesthetized 2193 rats: a microdialysis study Mena, F. V.; Baab, P. J.; Zielke, C. L.; In vivo glutamine hydrolysis in the formation of extracellular 2000 60 632-641 J Neurosci Res Zielke, H. R. glutamate in the injured rat brain Miyashita, K.; Abe, H.; Nakajima, T.; Glutamate release in the gerbil hippocampus after middle cerebral 1994 5 945-948 Neuroreport Ishikawa, A.; Nishiura-Suzuki, M.; Naritomi, artery occlusion H.; Tanaka, R.; Sawada, T. Molchanova, S.; Kbi, P.; Oja, S. S.; Interstitial concentrations of amino acids in the rat striatum during 2004 29 1519- Neurochem Res Saransaari, P. global forebrain ischemia and potassium-evoked spreading 1527 depression Morita, T.; Takahashi, M.; Takeuchi, T.; Changes in extracellular neurotransmitters in the cerebrum of 2005 67 1119- J Vet Med Sci Hikasa, Y.; Ikeda, S.; Sawada, M.; Sato, K.; familial idiopathic epileptic shetland sheepdogs using an 1126 Shibahara, T.; Shimada, A. intracerebral microdialysis technique and immunohistochemical study for glutamate metabolism Newcomb, R.; Palma, A. Effects of diverse omega-conopeptides on the in vivo release of 1994 638 95-102 Brain Res glutamic and gamma-aminobutyric acids Nilsson, P.; Hillered, L.; Ponten, U.; Changes in cortical extracellular levels of energy-related metabolites 1990 10 631-637 J Cereb Blood Flow Metab Ungerstedt, U. and amino acids following concussive brain injury in rats Asparagine Authors Title Year Vol Pages Journal Nilsson, P.; Ronne-Engstrom, E.; Flink, R.; Epileptic seizure activity in the acute phase following cortical impact 1994 637 227-232 Brain Res Ungerstedt, U.; Carlson, H.; Hillered, L. trauma in rat Qu, Y.; Li, Y.; Vandenbussche, E.; In vivo microdialysis in the visual cortex of awake cat. II: sample 2001 7 45-51 Brain Res Brain Res Protoc Vandesande, F.; Arckens, L. analysis by microbore HPLC-electrochemical detection and capillary electrophoresis-laser-induced fluorescence detection Qureshi, A. I.; Ali, Z.; Suri, M. F.; Shuaib, A.; Extracellular glutamate and other amino acids in experimental 2003 31 182-189 Crit Care Med Baker, G.; Todd, K.; Guterman, L. R.; intracerebral hemorrhage: an in vivo microdialysis study Hopkins, L. N. Radhakrishnan, R.; Sluka, K. A. Increased glutamate and decreased glycine release in the rostral 2009 457 141-145 Neurosci Lett ventromedial medulla during induction of a pre-clinical model of chronic widespread muscle pain Renno, W. M.; Mullet, M. A.; Williams, F. G.; Construction of 1 mm microdialysis probe for amino acids dialysis in 1998 79 217-228 J Neurosci Methods Beitz, A. J. rats Sandberg, M.; Butcher, S. P.; Hagberg, H. Extracellular overflow of neuroactive amino acids during severe 1986 47 178-184 J Neurochem insulin-induced hypoglycemia: in vivo dialysis of the rat hippocampus Sheng, W.; Hang, H. W.; Ruan, D. Y. In vivo microdialysis study of the relationship between lead-induced 2005 20 233-240 Environ Toxicol Pharmacol impairment of learning and neurotransmitter changes in the hippocampus Silverstein, F.
Load more

Recommended publications
  • Synthesis of Conformationally Constrained Glutamate Analogues and Their Preliminary Evaluation As Glutamate Transport Inhibitors
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Professional Papers Graduate School 2002 Synthesis of conformationally constrained glutamate analogues and their preliminary evaluation as glutamate transport inhibitors Travis Taylor Denton The University of Montana Follow this and additional works at: https://scholarworks.umt.edu/etd Let us know how access to this document benefits ou.y Recommended Citation Denton, Travis Taylor, "Synthesis of conformationally constrained glutamate analogues and their preliminary evaluation as glutamate transport inhibitors" (2002). Graduate Student Theses, Dissertations, & Professional Papers. 9450. https://scholarworks.umt.edu/etd/9450 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.
    [Show full text]
  • Exploring Novel Estrogen Receptors
    ExploringExploring novelnovel estrogenestrogen receptorsreceptors and How many drug targets? What are the relevant drug metabolizing enzymes? Tudor I. Oprea UNM Division of Biocomputing NMNM MLSCMLSC http://screening.health.unm.edu/ Support: New Mexico Molecular Libraries Screening Center (NIH MH074425) Strasbourg Summer School on Cheminformatics Obernai, Alsace, France, June 23 2008 The University of New Mexico ♦ Health Sciences Center Copyright © Tudor I. Oprea, 2007. All rights reserved SCHOOL OF MEDICINE MLIMLI inin NumbersNumbers NIHNIH RoadmapRoadmap InitiativeInitiative MolecularMolecular Libraries Libraries Initiative Initiative 44 Chemical Chemical Synthesis Synthesis MLSCNMLSCN (9+1) (9+1) PubChemPubChem ECCRECCR (6) (6) PredictivePredictive CentersCenters 99 centers centers (NLM)(NLM) ExploratoryExploratory ADMETADMET 11 NIH NIH intramural intramural CentersCenters (8)(8) 100100 x x 10 10 = = 1000 1000 assays assays CombiChemCombiChem ParallelParallel synthesis synthesis DOSDOS NotNot renewed renewed 44 centers centers + + DPI DPI 100k–500k100k–500k compounds compounds SAR matrix ~300,000 compounds Note: Subject http://nihroadmap.nih.gov The University of New Mexico > 1000 assays to change SCHOOL OF MEDICINE NMNM MLSCMLSC (3(3--yearyear summary)summary) U54MH074425U54MH074425 • 23 primary targets (62 assays) uploaded to PubChem • 38 targets total pipeline • ~ 2.4 million datapoints loaded into PubChem • Current throughput: 150,000 samples/week • first 6-plex (small GTP-ases) of the Roadmap • 2nd 6-plex (Bcl-2) also completed
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Poster Abstracts
    POSTER ABSTRACTS Society of Toxicology (MASOT) www.masot.org Fall 2015 Scientific Meeting October 13th, 2015 Abstract 01 Tracking Inflammatory Macrophage Accumulation in the Lung during Ozone- induced Lung Injury in Mice M Francis, M Mandal, C. Sun, H Choi, JD Laskin, DL Laskin Rutgers University, Piscataway, NJ Ozone induced lung injury is associated with an accumulation of pro- and antiinflammatory macrophages (MP) in the lung which have been implicated in tissue injury and repair. In these studies, we used in vivo tracking techniques to investigate the origin of cell. Initially we generated bone marrow (BM) chimeric mice by adoptive transfer of BM cells from GFP+ mice into irradiated C57BL/6 mice. After 4 weeks, mice were exposed to air or ozone (0.8 ppm, 3 h). Macrophages were isolated from lungs 24- 72 h later, stained with fluorescent labeled antibodies, and analyzed by flow cytometry. Approximately 98% of BM cells were found to be GFP+ while only 5% were GFP+ in control lungs. Ozone exposure resulted in a marked increase in infiltrating mature GFP+CD11b+F4/80+ MP into the lung. Two populations, Ly6CHi proinflammatory and Ly6CLo antiinflammatory were identified. Proinflammatory GFP+Ly6CHi MP increased rapidly after ozone and remained elevated, increases in antiinflammatory GFP+Ly6CLo were transient. To assess potential mechanisms mediating the accumulation of these MP subpopulations in the lung, we used mice lacking Ccr2, a chemokine receptor involved in proinflammatory MP trafficking. Loss of Ccr2 resulted in decreased numbers of infiltrating CD11b+ MP in the lung. This was due to a selective reduction in proinflammatory Ly6CHi MP.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Diagnosis and Treatment of Parkinson Disease: Molecules to Medicine
    Diagnosis and treatment of Parkinson disease: molecules to medicine Joseph M. Savitt, … , Valina L. Dawson, Ted M. Dawson J Clin Invest. 2006;116(7):1744-1754. https://doi.org/10.1172/JCI29178. Science in Medicine Parkinson disease (PD) is a relatively common disorder of the nervous system that afflicts patients later in life with tremor, slowness of movement, gait instability, and rigidity. Treatment of these cardinal features of the disease is a success story of modern science and medicine, as a great deal of disability can be alleviated through the pharmacological correction of brain dopamine deficiency. Unfortunately these therapies only provide temporary, though significant, relief from early symptoms and do not halt disease progression. In addition, pathological changes outside of the motor system leading to cognitive, autonomic, and psychiatric symptoms are not sufficiently treated by current therapies. Much as the discovery of dopamine deficiency led to powerful treatments for motor symptoms, recent discoveries concerning the role of specific genes in PD pathology will lead to the next revolution in disease therapy. Understanding why and how susceptible cells in motor and nonmotor regions of the brain die in PD is the first step toward preventing this cell death and curing or slowing the disease. In this review we discuss recent discoveries in the fields of diagnosis and treatment of PD and focus on how a better understanding of disease mechanisms gained through the study of monogenetic forms of PD has provided novel therapeutic targets. Find the latest version: https://jci.me/29178/pdf Science in medicine Diagnosis and treatment of Parkinson disease: molecules to medicine Joseph M.
    [Show full text]